Mrna immunotherapy for Epstein-Barr virus diseases
Part of Cancer, Infections clinical trials.
This study tests a new mRNA-based immunotherapy for diseases caused by the Epstein-Barr virus (EBV), such as certain cancers and conditions after a stem cell transplant. The treatment aims to help your immune system fight the virus and the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a disease caused by the Epstein-Barr virus (EBV), such as nasopharyngeal cancer, stomach cancer, lymphoma, or a complication after a stem cell transplant.
- You should be generally active and able to care for yourself (a score of 0 to 2 on the ECOG scale).
- You must be expected to live at least 3 more months.
- Your major organs (like heart, liver, and kidneys) must be working well enough, as shown by lab tests.
- You must not be pregnant and must agree to use effective birth control during the study and for 4 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new mRNA vaccine that helps your immune system fight cancer cells linked to the Epstein-Barr virus. It may be an option for people with advanced EBV-positive cancers that have not responded to standard treatments.
This trial tests an investigational mRNA vaccine (WGc-043) that aims to help your immune system fight EBV-positive lymphoma cells. If you have tried standard treatments and your lymphoma is still active, this vaccine might offer a new option.
This trial tests an investigational drug (WGc-043) for people with advanced solid tumors that are positive for the Epstein-Barr virus (EBV). The goal is to see if the drug is safe and how well it works, and it might help shrink tumors or slow their growth.
This trial tests a vaccine that may help prevent diseases caused by the Epstein-Barr virus (EBV) after a stem cell transplant. It could lower the risk of infections and related complications.
This is an early-stage study testing a new immune-based treatment for people with conditions caused by the Epstein-Barr virus (EBV), such as chronic active EBV or post-transplant lymphoproliferative disease. The study aims to see if the treatment is safe and can help control the disease.
This trial tests an experimental mRNA vaccine (mRNA-1189) to see if it can prevent Epstein-Barr virus (EBV) infection. It is for healthy adults 18 to 30 years old.
Hear when a new EBV-associated Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.